Lipocine Inc. Files 8-K with Office and Contact Details
Ticker: LPCN · Form: 8-K · Filed: 2024-12-13T00:00:00.000Z
Sentiment: neutral
Topics: corporate-filing, address-update
Related Tickers: LPCN
TL;DR
Lipocine Inc. (LPCN) filed an 8-K updating its address and contact info. Nothing major, just housekeeping.
AI Summary
Lipocine Inc. filed an 8-K on December 13, 2024, reporting an event. The filing details the company's principal executive offices located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah, 84108. The company's telephone number is (801) 994-7383. This report is filed under the Securities Exchange Act of 1934.
Why It Matters
This filing provides essential corporate information and contact details for Lipocine Inc., which is important for investors and stakeholders to stay informed about the company's operational base.
Risk Assessment
Risk Level: low — The filing is routine and primarily provides updated corporate contact and address information, with no indication of significant financial or operational changes.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- 675 Arapeen Drive, Suite 202, Salt Lake City, Utah, 84108 (location) — Principal executive offices
- (801) 994-7383 (phone_number) — Registrant's telephone number
- December 13, 2024 (date) — Date of Earliest Event Reported
FAQ
What is the primary purpose of this 8-K filing for Lipocine Inc.?
The primary purpose of this 8-K filing is to report current information as required by the Securities Exchange Act of 1934, specifically detailing the company's principal executive offices and contact information.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 13, 2024.
What is the exact address of Lipocine Inc.'s principal executive offices?
The exact address of Lipocine Inc.'s principal executive offices is 675 Arapeen Drive, Suite 202, Salt Lake City, Utah, 84108.
What is Lipocine Inc.'s telephone number?
Lipocine Inc.'s telephone number, including the area code, is (801) 994-7383.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
From the Filing
0001493152-24-049874.txt : 20241213 0001493152-24-049874.hdr.sgml : 20241213 20241213060657 ACCESSION NUMBER: 0001493152-24-049874 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20241213 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241213 DATE AS OF CHANGE: 20241213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241546653 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2024-12-13 2024-12-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): December 13, 2024     LIPOCINE INC.   (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   I Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit No.   Description 99.1   Corporate Presentation       104   Cover Page Interactive Data File (embedded within the Inline XBRL document)         SIG